By Karen Roman
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it is presenting new research at the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference, being held on December 1-4, 2025, in San Diego, California.
Acumen and JCR Pharmaceuticals are developing enhanced brain delivery technology for oligomer-selective antibodies, while the former will also announce recruitment results for Phase 2 of the ALTITUDE-AD clinical trial, Acumen said.
“This research is advancing the understanding of two major challenges in the treatment of Alzheimer’s disease – targeted drug delivery into the CNS and clinical trial execution,” said Jim Doherty, PhD, Acumen Pharmaceuticals President and Chief Development Officer.
READ MORE
NYSE Firesides Scheduled Dec 9, 2025 & Feb 3, 2026
Never Miss our Weekly Highlights HERE
